The Race for Oral Peptide Drugs: How Rybelsus Broke the Rules

For decades, peptides had to be injected. Oral semaglutide (Rybelsus) proved that wrong with the SNAC absorption enhancer. Now orforglipron and other technologies are racing to make peptide injections obsolete.

Why peptides can’t be taken by mouth (usually)

The GI tract destroys peptides through three barriers: enzymatic degradation (pepsin in the stomach, trypsin and chymotrypsin in the intestine), poor membrane permeability (peptides are too large and hydrophilic to cross the intestinal epithelium), and first-pass metabolism in the liver. The result: oral bioavailability for most unmodified peptides is effectively 0%. Only very small peptides like collagen peptides (di- and tripeptides) can use the active PepT1 transporter for oral absorption.

How Rybelsus works: the SNAC breakthrough

Oral semaglutide (Rybelsus, FDA approved 2019) uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to create a protective microenvironment in the stomach. SNAC locally buffers pH to ~5–6 (inactivating pepsin), promotes the monomeric peptide form, and transiently enhances transcellular absorption across the gastric epithelium. Oral bioavailability is only ~0.4–1%, so the 14 mg tablet delivers roughly the same exposure as a 0.5 mg injection. The strict dosing rules — empty stomach, 4 oz water only, 30-minute fast — exist because food dilutes the SNAC microenvironment.

Orforglipron: the non-peptide approach

Eli Lilly’s orforglipron sidesteps the oral peptide problem entirely. It is a non-peptide small molecule that activates the GLP-1 receptor — no SNAC, no fasting, no dosing restrictions. Phase II data showed up to 14.7% weight loss at 36 weeks. Phase III trials are underway. If approved, it would be the first oral non-peptide GLP-1 agonist, potentially expanding the treatable market 2–3x by eliminating the needle barrier.

Other oral delivery technologies

The field is advancing rapidly beyond SNAC. Permeation enhancers like C10 (sodium caprate) open paracellular tight junctions. Nanoparticle encapsulation in PLGA or chitosan protects peptides from degradation. Microneedle capsules (MIT’s SOMA device) inject peptide into the gut wall from inside a swallowed capsule. Rani Therapeutics’ RaniPill uses a spring-loaded needle deployed in the intestine. Mycapssa (oral octreotide for acromegaly) is already FDA-approved using TPE (transient permeability enhancer) technology, proving the concept extends beyond semaglutide.

Why it matters: access and equity

Needle phobia affects 20–25% of adults. Injectable drugs require cold chain storage, sharps disposal, and carry stigma. An effective oral GLP-1 with no restrictions would enable primary care prescribing at scale, reaching patients who currently decline injection-based treatment. The technologies developed for oral GLP-1 could eventually enable oral insulin, oral calcitonin, and oral PTH analogs — each eliminating daily injections for millions of patients.

Related dictionary entries

← Back to Blog  ·  Browse Dictionary

Part of the PeptideBond.com education network